Browsing Tag
UCB
8 posts
Antengene–UCB autoimmune deal: Why the $1.1bn ATG-201 partnership could reshape B-cell targeting therapies
Antengene licenses ATG-201 to UCB in a $1.1B autoimmune drug deal. Discover why bispecific antibodies are becoming the next frontier in immunology.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
UCB’s BIMZELX shows sustained inflammation control at three years in psoriatic arthritis and axial spondyloarthritis
Discover how UCB’s BIMZELX three-year data show lasting inflammation control in PsA and axSpA—find out what’s next for the treatment landscape.
CBC Group redefines CNS care in China with UCB portfolio acquisition
Singapore-based CBC Group, Asia’s largest healthcare-dedicated asset management firm, has finalized its strategic acquisition of UCB’s mature neurology…
UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China…
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global…
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its…
Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women
Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis…